ClinicalTrials.Veeva

Menu

Medium Dose of Cytarabine and Mitoxantrone (HAM)

S

Southern University of Science and Technology

Status

Unknown

Conditions

Acute Myelogenous Leukemia
Chemotherapy

Treatments

Drug: Mitoxantrone
Device: Flow Cytometer
Drug: Cytarabine

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

By observation of the inpatients in shenzhen people's hospital,research the curative effect of the two chemotherapy schemes on AML-High dose of cytarabine and HAM.

Full description

The patients of AML in shenzhen people's hospital were randomly divided into two therapy groups.One group was treated by High dose of cytarabine ,and the other was HAM.Evaluate the two chemotherapy schemes by bone marrow suppression time and patient survival time.

Enrollment

250 estimated patients

Sex

All

Ages

14 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

people diagnosed as AML

Exclusion criteria

  • acute promyeloytic leukemia

Trial design

250 participants in 2 patient groups

high dose of cytarabine
Description:
high dose of cytarabine
Treatment:
Device: Flow Cytometer
Drug: Cytarabine
Drug: Mitoxantrone
HAM
Description:
medium dose of cytarabine and mitoxantrone
Treatment:
Device: Flow Cytometer
Drug: Cytarabine
Drug: Mitoxantrone

Trial contacts and locations

1

Loading...

Central trial contact

Yixuan Cao, master

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems